Clinical Trials: Colorectal Cancer. Alabama. Florence; Research Site of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment Disease Category Listing (426): Colorectal Cancer CenterWatch Listing of Clinical Research Trials for Colorectal Cancer of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment MULTICENTER STUDY OF ABX-EGF MONOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER progression in patients with metastatic colorectal cancer treated with ABX-EGF metastatic colorectal cancer. ABX-EGF is well-tolerated, with mild to moderate Clinical Trial: ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Chemotherapy. This study is currently recruiting patients. Sponsored by: Jonsson Comprehensive Cancer Center. Information provided by: patients with metastatic colorectal cancer treated with monoclonal antibody ABX-EGF after failing prior Abgenix - Investor Relations - Press Release Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human PANITUMUMAB (ABX-EGF) MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): AN UPDATED ANALYSIS pretreated patients with metastatic colorectal cancer, including patients with lower PANITUMUMAB (ABX-EGF) MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): AN Abgenix, Amgen Begin Colorectal Cancer Pivotal Trial Of ABX-EGF. Abgenix Inc. and partner Amgen Inc. are starting a pivotal trial for use of ABX-EGF as a third-line monotherapy in colorectal cancer patients. Beyond colorectal cancer, ABX-EGF is in Phase II trials for non-small-cell lung cancer, renal-cell cancer Clinical Trial: Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non- Monoclonal Antibody ABX-EGF in Treating ABX-EGF in patients with renal, prostate, pancreatic, non-small cell lung, colorectal, esophageal, or gastroesophageal junction cancer Fox Chase Cancer Center: Monoclonal Antibody Has Promising Activity monoclonal antibody called ABX-EGF shows anti-cancer activity in patients with study demonstrates that ABX-EGF has promising activity against advanced colorectal cancer and can be Zacks Investment Research: Profit from the Pros Phase II trial of ABX-EGF in colorectal cancer are expected at the upcoming are under way; colorectal cancer, renal cell cancer, non-small cell lung cancer and prostate cancer BioSpace News for ABX-EGF Abgenix (ABGX) Announces ABX-EGF Enters Pivotal Trial In Advanced Colorectal Cancer Patients. Read More (1 Preliminary Phase 2 Data Suggest ABX-EGF Has Single-Agent Anti-Tumor British Columbia Health Industries Network Press Release human monoclonal antibody, ABX-EGF, as a third-line monotherapy in colorectal cancer patients, with enrollment as part of a comprehensive global development program for ABX-EGF. National Cancer Institute - Clinical Trials (PDQ) with metastatic colorectal cancer treated with monoclonal antibody ABX-EGF, irinotecan, leucovorin pharmacokinetics of monoclonal antibody ABX-EGF when administered with this Colorectal Cancer VENTURA COUNTY. HEMATOLOGY-ONCOLOGY. SPECIALISTS. Clinical Trials. Colorectal Cancer. Adjuvant. Roche-Xelox N016968: A Phase III study comparing Xeloda and Oxaliplatin vs. ABX-EGF-167: A Phase II study of ABX-EGF, a monoclonal antibody against human EGFr as a single agent third line CancerSource.com News of ABX-EGF, an anti-cancer monoclonal antibody colorectal cancer who have failed prior chemotherapy treatment. Patients will receive intravenous infusions of 2.5 mg/kg of ABX-EGF Abgenix Says Drug Is Effective Against Kidney Cancer The company's ABX-EGF is one of a closely watched new class of epidermal growth factor drugs. 88 patients with advanced kidney cancer responded to ABX-EGF, or 6% of patients in the II studies of ABX-EGF against colorectal, lung and prostate cancer. The drug is Science Blog -- Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research on many major human tumor types including renal, prostate, colorectal, head and neck, and breast Pipeline Insight: Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline Targeted Therapies alter the treatment landscape for colorectal cancer. This report examines the for cancer. For colorectal cancer, Erbitux represents the class. Amgen/Abgenix's ABX-EGF is likely to Pipeline Insight: Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline Targeted Therapi: Market Market research, company and industry reports and premium quality market analysis. and Erbitux into the colorectal cancer market will raise the standard launched for cancer. For colorectal cancer, Erbitux represents the class. Amgen/Abgenix's ABX-EGF is likely to San Antonio Cancer Institute: Clinical Trials - Selected Phase 1 COLORECTAL CANCER (Previously Untreated/Metastatic) ABX-EGF + FOLFIRI. ABX-EGF + FOLFIRI is a Phase II 5-fluorouracil) in patients with colorectal cancer who have received no prior Chemie.DE News-Center: Abgenix Announces Initiation of Phase II Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer 12/31/2001 - Abgenix, Inc. Chemie.DE News: Abgenix Announces Initiation of Phase II Clinical 28.12.2001 Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. Interim Phase 2 Data Demonstrate Single-Agent Antitumor Activity 800-84-AMGEN INTERIM PHASE 2 DATA DEMONSTRATE SINGLE-AGENT ANTITUMOR ACTIVITY WITH ABX-EGF IN ADVANCED COLORECTAL CANCER CHICAGO, IL, May 31 ASCO - Browse by Meeting - ABX-EGF monotherapy in patients (pts) Category: Gastrointestinal Cancer - Colorectal/Liver SubCategory: Colorectal Cancer (including liver metastases) ABX-EGF monotherapy in ASCO - Virtual Meeting - Presentation View Slides Associated abstract: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. ABX-EGF monotherapy in patients (pts) with metastatic colorectal ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis J. R. Hecht , A. Patnaik , I. Malik Colorectal Cancer Week -- News and information about the prevention, Colorectal Cancer Week - News and information about the prevention, diagnosis and treatment of Colon and Rectal Cancer. The site is the most Study Posting (3314) -- Trial #58979, Colorectal Cancer, Richardson, Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Study Posting (3416) -- Trial #62289, Colorectal Cancer, Summary: A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express BioSpace News for ABX-EGF (8/25/04) Abgenix (ABGX) Announces ABX-EGF Enters Pivotal Trial In Advanced Colorectal Cancer Patients Read More (1/20/04) ABX-EGF monotherapy in patients (pts) with metastatic colorectal Abstract. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. JR Hecht , A. Patnaik Clinical Trial: ABX-EGF Monotherapy in Subjects with Metastatic ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer. Condition, Treatment or Intervention, Phase. Colorectal Cancer Metastases, Drug: ABX-EGF, Phase Clinical Trial: ABX-EGF in Treating Patients With Metastatic Official Title: Phase II Study of Monoclonal Antibody ABX-EGF in Patients With Metastatic Colorectal Cancer That Failed Prior Chemotherapy Comprising ABX-EGF in the Treatment of Colorectal Cancer J. Randolph Hecht VEGF Inhibition in Breast and Colorectal Cancer: Where are we now and where are we going? J. Randolph Hecht. Etc. Growth Factors. EGF. COX2. Etc. ABX-EGF in the Treatment of Colorectal Cancer J. Randolph Hecht Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline For colorectal cancer, Erbitux represents the class. Amgen/Abgenix's ABX-EGF is likely to be the main competition for Erbitux but ABX-EGF's third-line BC Biotech Internet - INTERIM PHASE 2 DATA DEMONSTRATE SINGLE INTERIM PHASE 2 DATA DEMONSTRATE SINGLE-AGENT ANTITUMOR ACTIVITY WITH ABX-EGF IN ADVANCED COLORECTAL CANCER Admin Location: Home IMS Health - Pharmaceutical market intelligence Compound. Type of action. Developers. Phase (colorectal cancer). ABX-EGF. MAb, EGFR. Abgenix, Amgen. III. Canvaxin. therapeutic vaccine. CancerVax. III. IGN101. Abgenix - Product Development clinical studies. In January 2004, Amgen initiated pivotal clinical trials for ABX-EGF in third line colorectal cancer. Abgenix and Interim Phase 2 Data Demonstrate Single-Agent Antitumor Activity patients with metastatic colorectal cancer,” said Dr. Meropol. “The fully human nature of ABX-EGF confers potential benefits